Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Ambev

Global Payments

Johnson & Johnson

Lockheed Martin

McCormick

Reynolds Consumer Products

Molson Coors Brewing

IMF October Buys: The 13 Stocks Added To My Fund

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

QIAGEN

Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.

Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M

Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates

FRANKLIN LAKES, N.J., Nov. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021.

BD Announces Fourth Fiscal Quarter And Full Year 2021 Results; Issues Fiscal Year 2022 Guidance

FRANKLIN LAKES, N.J., Nov. 4, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, an increase of 4.8% from the previous quarter.

BD Board Increases Dividend for 50th Consecutive Year, Authorizes 10 Million Additional Share Repurchases

Becton Dickinson & Co. BDX, +1.70% reported Thursday fiscal fourth-quarter profit and revenue that rose above expectations, with strength in its medical and interventional businesses, and in international sales. Net income for the quarter to Sept.

Becton Dickinson net profit more than doubles, revenue beat expectations

Becton Dickinson & Co. BDX, +1.70% said Thursday it will raise its dividend by nearly 5% and that it set a 10 million share repurchase program that could be valued at nearly $2.5 billion at current prices. The new quarterly dividend of 87 cents a share, up from 83 cents, will be payable Dec. 31 to shareholders of record on Dec. 10.

Becton Dickinson boosts dividend by 5%, sets new repurchase program valued at nearly $2.5 billion

FRANKLIN LAKES, N.J., Oct. 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.

BD Collaborates with U.S. Government on Development of COVID-19 Combination Diagnostic Tests

FRANKLIN LAKES, N.J., Oct. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a virtual investor day on Friday, Nov. 12, 2021 at 8 a.m.

BD to Host Investor Day on November 12

Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated smartphone app. The BD Veritor At-Home COVID-19 Test, which U.S. regulators authorized in August, also automatically reports results to federal and state public health authorities.

Becton Dickinson Starts Selling New At-Home Rapid COVID-19 Tests

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?

FRANKLIN LAKES, N.J., Oct. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has started to ship the first over-the-counter (OTC) COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret testing results, and the test is now available for purchase online in Amazon's store.

BD Begins Shipments Of First Smartphone Interpreted Over-The-Counter Rapid COVID-19 Test

AutoNation

Ternium

Becton, Dickinson and Company (BDX), Ternium (TX) & AutoNation (AN) are three must-buy efficient stocks that can enrich your portfolio now.

3 Must-Buy Efficient Stocks to Boost Portfolio Returns

FRANKLIN LAKES, N.J., Oct. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Carrie L.

BD Names Dr. Carrie Byington To Board Of Directors

FRANKLIN LAKES, N.J., Oct. 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new strategy to advance environmental, social and governance (ESG) initiatives, as well as a suite of goals for 2030 and beyond that focus on enhancing stewardship of the company, the planet, community and human health.

BD Launches New 'Together We Advance' Environmental, Social, Governance Strategy; Announces 2030+ Goals to Enhance Stewardship of Human Health, Communities and the Planet

BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.

BD's (BDX) New Manufacturing Facility to Boost Supply Readiness

BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.

BD's (BDX) Rotarex Atherectomy System Gets FDA 510 (k) Clearance

BD develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products among other products.

Becton, Dickinson And Company: R&D And M&A Could Make The Price Spike By 47%

FRANKLIN LAKES, N.J., Oct. 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through increased manufacturing capacity and domestic supply.

BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Vaccination Agility and Preparedness

Becton, Dickinson And Co (NYSE: BDX) has received FDA 510(k) clearance for expanded indications for the Rotarex Atherectomy System. Related:   BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance.

BDX's Rotarex Atherectomy System Wins FDA Indication Expansion Approval

FRANKLIN LAKES, N.J., Oct. 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance for expanded indications from the U.S. Food and Drug Administration (FDA) for the Rotarex™ Atherectomy System.

BD Announces 510(k) Clearance of Expanded Indications for the Rotarex™ Atherectomy System

Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank

Bear Of The Day: Becton, Dickinson and Co (BDX)

FRANKLIN LAKES, N.J., Oct. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its fiscal 2021 fourth quarter and full year financial results on Thursday, Nov. 4, 2021.

News for Becton, Dickinson and Co. Stock (BDX)